fashion -WSS

fashion

author：focus 2025-09-06 02:13:30 - browse：139

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： UHS says company favors patients whose insurance pays more

focus

WSS

Videos point to link between seizures and unexplained toddler deaths

What causes rare myocarditis in young men after Covid vaccines?

Senate panel puts off hardest PBM reforms for another day

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

leisure time

fashion

Wikipedia

Medicare details structure of new drug price negotiation program

UHS says company favors patients whose insurance pays more

In age of alternative facts, a scholarly course on calling out crap

Federal weight loss drug coverage is 30 years out of date

How to save PrEP access — and even expand it

New Alzheimer's drugs heat up race for early detection blood tests

Wildfire smoke exposes gaps in outdoor worker protections

Why patients can’t get everything they want on drug pricing

At least 13 dead in Texas as scorching temps continue

Democrats decry new health bill for going easy on private equity

hotspot

What it's like to live with paralysis for one psychologist

Why psychiatrists like me stop taking insurance

Truvian presents data for its desktop blood

STAT Report: Patient voices and perspectives

Rise in cancer among younger people worries and puzzles doctors

New lawsuit accuses health insurer Cigna of denying claims in bulk

focus

focus

focus

hotspot